Quentis Therapeutics
Developing innovative immuno-therapeutics to combat ER stress and empower the immune system in the fight against cancer
Developing innovative immuno-therapeutics to combat ER stress and empower the immune system in the fight against cancer
Quentis Therapeutics is a biotechnology startup founded in 2016 that is focused on developing innovative immuno-therapeutics to combat ER stress and empower the immune system in the fight against cancer. The company's slogan, "Developing innovative immuno-therapeutics to combat ER stress and empower the immune system in the fight against cancer," reflects its commitment to addressing ER stress across various diseases. Quentis Therapeutics' latest funding, a $1.00M grant investment, was received on 03 December 2018 from the New York City Economic Development Corporation (NYCEDC). This investment signifies the recognition and support of Quentis Therapeutics' efforts to enhance the immune system's capacity to combat cancer, thereby providing patients with advanced cancer treatment options. The company operates within the industries of Biotechnology, Health Care, and Health and Wellness. Although the headquarters location is not specified, Quentis Therapeutics' focus on revolutionary immuno-therapies positions it as an innovative player in the biotechnology sector with significant potential for impact and growth.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $1.00M | 1 |
|
03 Dec 2018 |
| Series A | $48.00M | 7 |
|
27 Feb 2018 |
No recent news or press coverage available for Quentis Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
